First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure

• Main Authors: Zwirner, Stefan, Rmilah, Anan A. Abu, Klotz, Sabrina, Pfaffenroth, Bent, Kloevekorn, Philip, Moschopoulou, Athina A., Schuette, Svenja, Haag, Mathias, Selig, Roland, Li, Kewei, Zhou, Wei, Nelson, Erek, Poso, Antti, Chen, Harvey, Amiot, Bruce, Jia, Yao, Minshew, Anna, Michalak, Gregory, Cui, Wei, Rist, Elke, Longerich, Thomas, Jung, Birgit, Felgendreff, Philipp, Trompak, Omelyan, Premsrirut, Prem K., Gries, Katharina, Muerdter, Thomas E., Heinkele, Georg, Wuestefeld, Torsten, Shapiro, David, Weissbach, Markus, Koenigsrainer, Alfred, Sipos, Bence, Ab, Eiso, Zacarias, Magdalena Ortiz, Theisgen, Stephan, Gruenheit, Nicole, Biskup, Saskia, Schwab, Matthias, Albrecht, Wolfgang, Laufer, Stefan, Nyberg, Scott, Zender, Lars
• Other Authors: School of Biological Sciences
• Format: Article
• Language: English
• Published: 2024
• Subjects: Medicine, Health and Life Sciences; Drug discovery and development; Liver failure
• Online Access: https://hdl.handle.net/10356/178695
• Institution: Nanyang Technological University

Diminished hepatocyte regeneration is a key feature of acute and chronic liver diseases and after extended liver resections, resulting in the inability to maintain or restore a sufficient functional liver mass. Therapies to restore hepatocyte regeneration are lacking, making liver transplantation th...